|Bid||17.50 x 4000|
|Ask||18.70 x 800|
|Day's Range||17.95 - 18.70|
|52 Week Range||15.60 - 36.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2018 - Nov 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.22|
The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.
Stocks that moved substantially or traded heavily Thursday: Progenics Pharmaceuticals Inc., down $1.30 to $6 The company reported disappointing results from a study of an imaging compound used in prostate ...
Shares retreated after the company provided Wall Street with an updated regulatory timeline. Here's what investors need to know.
Shares of Acorda Therapeutics Inc. slid 19% Thursday, after the company said the U.S. Food and Drugs Administration has extended the review period for a treatment for symptoms of Parkinson Disease. The extension comes after Acorda submitted additional information on its Inbrija, an inhaled levodopa therapy that aims to reduce off times, or the periods when standard levodopa treatment stops working. The FDA determined that the additional information constituted a major amendment that would take longer to review. The regulator moved the review date back to Jan. 5, 2019 from Oct. 5, 2018. Parkinson's is a progressive neurodegenerative disorder that affects about 1 million people in the U.S. and 1.2 million people in Europe. Acorda shares have fallen 13.8% in 2018, while the S&P 500 has gained 8.1%.
Acorda Therapeutics, Inc. (ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of INBRIJA™ (levodopa inhalation powder) from October 5, 2018 to January 5, 2019. This extension is related to recent submissions Acorda made in response to requests from FDA for additional information on chemistry, manufacturing and controls (CMC). FDA determined that these submissions constitute a major amendment and will take additional time to review.
Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra
NEW YORK, NY / ACCESSWIRE / September 11, 2018 / Acorda shares were deep in the red after a disappointing court ruling on Monday. A U.S. District Court of Appeals has held up a lower court ruling invalidating key patents on Ampyra, the company’s multiple sclerosis drug that accounts for most of its sales. Shares of Avid Bioservices traded fairly flat during the day but soared in after-hours extended trading after reporting stellar first quarter financial results.
Shares of Acorda Therapeutics Inc. plunged 21% toward an 8-month low in midday trade Monday, after a disappointing ruling a federal appeals court on patents pertaining to its multiple sclerosis treatment, Ampyra. The company said the U.S. Court of Appeals upheld by a 2-to-1 vote the U.S. District Court of Delaware's decision to invalidate four Ampyra patents. That validates the District Court's ruling on March 31, 2017, which invalidated patents pertaining to Ampyra extended release tablets. Acorda said it was reviewing the decision and its options, including a further appeal. "We are disappointed by the Court's decision, as we continue to believe that our AMPYRA patents reflected true invention and were valid," Chief Executive Ron Cohen said in a statement. "Following the Court's original decision in 2017, we prepared a contingency plan that we could face generic competition, implementing a comprehensive corporate restructuring and bolstering our balance sheet." Despite the stock's sharp selloff, it has gained 1.2% year to date, while the S&P 500 has tacked on 7.7%.
Acorda Therapeutics, Inc. (ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of Delaware’s decision to invalidate four AMPYRA patents. This decision affirms the District Court’s ruling on March 31, 2017 invalidating U.S. Patent Nos. 8,663,685 (the ‘685 patent), 8,007,826 (the ‘826 patent), 8,440,703 (the ‘703 patent), and 8,354,437 (the ‘437 patent) pertaining to AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. Acorda’s U.S. Patent No. 5,540,938 (the ‘938 patent), previously upheld by the District Court, expired on July 30, 2018.
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acorda ...
Acorda Therapeutics, Inc. (ACOR) today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acorda’s Chief of Business Operations, will assume responsibility for the company’s Chelsea, MA manufacturing facility, which produces INBRIJA™ (levodopa inhalation powder), as well as for the external manufacturing of AMPYRA® (dalfampridine). Burkhard Blank, M.D., Acorda’s Chief Medical Officer, will assume responsibility for Acorda’s Pharmaceutical Development and Technical Operations teams.
Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.
Acorda (ACOR) delivered earnings and revenue surprises of 86.67% and 19.10%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Acorda Therapeutics, Inc. (NASDAQ: ACOR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 8:30 AM Eastern ...
The Ardsley, New York-based company said it had net income of 98 cents per share. Earnings, adjusted for one-time gains and costs, came to $1.40 per share. The results exceeded Wall Street expectations. ...
ARDSLEY, N.Y.-- -- INBRIJA™ NDA under FDA review; PDUFA date October 5, 2018 AMPYRA® 2Q 2018 net sales of $150.3 million; reiterating 2018 guidance of $330-$350 million Awaiting AMPYRA patent decision from U.S. Court of Appeals Acorda Therapeutics, Inc. provided a financial and pipeline update for the quarter ended June 30, 2018. “Our outstanding quarter reflected the continued excellence of our specialty ...